Qilu Pharmaceutical's Apremilast Tablets Approved as China's Second Generic for Plaque Psoriasis Treatment

On June 2, the official website of the National Medical Products Administration showed that the apremilast tablets developed by Qilu Pharmaceutical have been approved for marketing. This is the second generic apremilast product to be marketed in China.

Apremilast is an orally administered small molecule phosphodiesterase 4 (PDE4) inhibitor originally developed by Amgen, which is specific to cyclic adenosine monophosphate (cAMP). The inhibition of PDE4 leads to increased intracellular levels of cAMP. This product is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Psoriasis is a serious chronic inflammatory disease with a long course and prone to recurrence. The main symptoms are raised red scaly plaques on the skin, commonly occurring on the elbows, knees, or outer sides of the scalp, but can also appear on any part of the body. According to statistics, there are approximately 125 million psoriasis patients globally, with about 6.5 million patients in China.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position; for republication, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.